Clinical Trials
2 trialsNCT05691504 2026-05-13
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04001777 2025-10-01
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
Ascentage Pharma Group Inc.
Phase 1 Active not recruiting